Biofrontera Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Biofrontera şirketinin toplam hissedar öz sermayesi $6.1M ve toplam borcu $4.7M olup, bu da borç-öz sermaye oranını 77.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $24.8M ve $18.7M dir.

Anahtar bilgiler

77.74%

Borç/özkaynak oranı

US$4.72m

Borç

Faiz karşılama oranı	n/a
Nakit	US$6.33m
Eşitlik	US$6.07m
Toplam yükümlülükler	US$18.72m
Toplam varlıklar	US$24.79m

Son finansal sağlık güncellemeleri

Recent updates

Analiz Makalesi • Jan 23

There's No Escaping Biofrontera Inc.'s (NASDAQ:BFRI) Muted Revenues Despite A 42% Share Price Rise

Those holding Biofrontera Inc. ( NASDAQ:BFRI ) shares would be relieved that the share price has rebounded 42% in the...

Analiz Makalesi • Oct 04

Benign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Its Share Price

You may think that with a price-to-sales (or "P/S") ratio of 0.3x Biofrontera Inc. ( NASDAQ:BFRI ) is definitely a...

Yeni Anlatı • May 05

FDA Approval And Product Expansion Will Unlock New Markets

FDA approval for expanded Ameluz use and restructuring agreements enhance margins, supporting future revenue growth through increased average sales size and reduced costs.

Analiz Makalesi • Feb 27

Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues

Biofrontera Inc.'s ( NASDAQ:BFRI ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong buy right...

Analiz Makalesi • Sep 28

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story

Biofrontera Inc. ( NASDAQ:BFRI ) shares have continued their recent momentum with a 25% gain in the last month alone...

Analiz Makalesi • Aug 09

Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce

Those holding Biofrontera Inc. ( NASDAQ:BFRI ) shares would be relieved that the share price has rebounded 40% in the...

Analiz Makalesi • May 24

Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

Biofrontera Inc. ( NASDAQ:BFRI ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...

Analiz Makalesi • Dec 30

Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%

Unfortunately for some shareholders, the Biofrontera Inc. ( NASDAQ:BFRI ) share price has dived 28% in the last thirty...

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BFRI 'nin kısa vadeli varlıkları ( $13.2M ) kısa vadeli yükümlülüklerini ( $10.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: BFRI şirketinin kısa vadeli varlıkları ( $13.2M ) uzun vadeli yükümlülüklerini ( $7.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BFRI şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: BFRI şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 77.7% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BFRI şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: BFRI tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/17 12:57
Gün Sonu Hisse Fiyatı	2026/06/17 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Biofrontera Inc. 2 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Bruce Jackson	Benchmark Company
Jonathan Aschoff	Roth Capital Partners

Biofrontera Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Biofrontera Receives A Non-Compliance Letter from the Nasdaq Stock Market

Biofrontera Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Nasdaq Determines to Grant Biofrontera Inc. an Extension of 180 Calendar Days from November 22, 2023 to Regain Compliance

Biofrontera Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Continued Listing Requirement Under Nasdaq Listing Rule 5550(b)(1)

Recent updates

New minor risk - Share price stability

First quarter 2026 earnings: EPS and revenues miss analyst expectations

New major risk - Market cap size

New minor risk - Profitability

Biofrontera Inc. to Report Q1, 2026 Results on May 14, 2026

Biofrontera Inc., Annual General Meeting, Jun 11, 2026

New major risk - Financial position

Consensus estimates of losses per share improve by 70%

Full year 2025 earnings released: US$0.91 loss per share (vs US$3.22 loss in FY 2024)

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development Of Ameluz Photodynamic Therapy For Moderate To Severe Acne Vulgaris

U.S. Patent Board Rules Sun Pharmaceutical Industries, Inc’s Patent Is Unpatentable After Biofrontera Challenge

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz®? for Actinic Keratoses on Trunk and Extendedities

Biofrontera Inc. Announces U.S. Food and Drug Administration Filing Acceptance of Supplemental New Drug Application for Ameluz PDT in Superficial Basal Cell Carcinoma

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

There's No Escaping Biofrontera Inc.'s (NASDAQ:BFRI) Muted Revenues Despite A 42% Share Price Rise

Biofrontera Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

New minor risk - Share price stability

Biofrontera Inc. Completes Transfer of Ameluz®? and RhodoLED®? FDA Approval and Associated Intellectual Property Portfolio

Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (Snda) for the Treatment of Superficial Basal Cell Carcinoma with Ameluz®?-Pdt

Third quarter 2025 earnings: EPS misses analyst expectations

New minor risk - Profitability

New minor risk - Profitability

Biofrontera Inc. to Report Q3, 2025 Results on Nov 12, 2025

Biofrontera Inc. (NasdaqCM:BFRI) completed the acquisition of US Assets related to Ameluz and RhodoLED of Biofrontera AG.

Forecast breakeven date pushed back to 2027

Benign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Its Share Price

Price target decreased by 7.7% to US$6.00

New minor risk - Profitability

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz Topical Gel

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz®? Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Consensus EPS estimates fall by 33%

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer, Effective August 25, 2025

Biofrontera Inc. to Report Q2, 2025 Results on Aug 13, 2025

Consensus EPS estimates upgraded to US$0.99 loss

Biofrontera Inc. announced that it expects to receive $11 million in funding from Aigh Capital Management, LLC, Rosalind Advisors, Inc.

New minor risk - Share price stability

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic Acid HCI)

Biofrontera Receives A Non-Compliance Letter from the Nasdaq Stock Market

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Biofrontera Inc. Announces New Patent Protection on Ameluz®? until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz®? Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Biofrontera Inc. to Report Q1, 2025 Results on May 15, 2025

FDA Approval And Product Expansion Will Unlock New Markets

Biofrontera Inc., Annual General Meeting, Jun 12, 2025

Forecast breakeven date pushed back to 2027

New major risk - Financial position

Full year 2024 earnings: EPS and revenues miss analyst expectations

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz®? Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Biofrontera Inc. to Report Q4, 2024 Results on Mar 21, 2025

Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. announced that it has received $4.2 million in funding

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Biofrontera Inc. to Report Nine Months, 2024 Results on Nov 13, 2024

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces Database Lock of Phase 3 Study of Ameluz-Photodynamic Therapy in Treatment of Superficial Basal Cell Carcinoma

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story

Consensus EPS estimates fall by 17%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce

Biofrontera Inc. to Report Q2, 2024 Results on Aug 14, 2024

Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

Consensus EPS estimates fall by 31%

First quarter 2024 earnings: EPS and revenues miss analyst expectations